Callan Family Office’s AbbVie ABBV Stock Holding History

Callan Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.2M	Buy	60,748 +2,350	+4%	+$521K	0.3%	65
2025 Q4	$13.3M	Buy	58,398 +17,044	+41%	+$3.88M	0.29%	66
2025 Q3	$9.58M	Buy	41,354 +6,354	+18%	+$1.29M	0.31%	64
2025 Q2	$6.5M	Buy	35,000 +16,487	+89%	+$3.06M	0.21%	117
2025 Q1	$3.88M	Sell	18,513 -2,592	-12%	-$504K	0.29%	77
2024 Q4	$3.75M	Buy	21,105 +17,886	+556%	+$3.29M	0.24%	79
2024 Q3	$636K	Buy	3,219 +106	+3%	+$19.8K	0.11%	92
2024 Q2	$534K	Buy	3,113 +729	+31%	+$121K	0.1%	80
2024 Q1	$434K	Sell	2,384 -114	-5%	-$19.6K	0.1%	61
2023 Q4	$387K	Buy	2,498 +114	+5%	+$16.6K	0.1%	65
2023 Q3	$355K	Sell	2,384 -690	-22%	-$101K	0.09%	64
2023 Q2	$414K	Sell	3,074 -425	-12%	-$62.3K	0.11%	69
2023 Q1	$558K	Buy	3,499 +1,487	+74%	+$227K	0.14%	89
2022 Q4	$325K	Buy	+2,012	New	+$309K	0.1%	78

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Callan Family Office's ABBV Position: Q1 2026 in Review

Callan Family Office increased its AbbVie (ABBV) stake by 4% in Q1 2026, buying an estimated $521K and bringing the position to 60,748 shares worth $13.2M. The position accounts for 0.3% of the portfolio, ranked #65.

Callan Family Office first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $13.3M in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Callan Family Office held 60,748 shares of AbbVie worth $13.2M as of Q1 2026.
Callan Family Office bought 2,350 AbbVie shares in Q1 2026, an estimated $521K.
AbbVie made up 0.3% of Callan Family Office's portfolio in Q1 2026, its #65 holding.
Callan Family Office first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
Callan Family Office's AbbVie position peaked at $13.3M in Q4 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.